Last reviewed · How we verify
Men C conjugate
Men C conjugate is a Biologic drug developed by Public Health England. It is currently FDA-approved.
Men C conjugate vaccine is used to prevent Meningococcal Infections and is also studied for its potential in preventing Pneumococcal Infections. It is administered as part of a combination vaccine that includes DTaP/Hib/IPV and Pneumococcal Conjugate Vaccines.
At a glance
| Generic name | Men C conjugate |
|---|---|
| Sponsor | Public Health England |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer (PHASE1)
- Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (PHASE1)
- Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines (PHASE4)
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
- Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (PHASE4)
- Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (PHASE3)
- Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants (PHASE3)
- Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Men C conjugate CI brief — competitive landscape report
- Men C conjugate updates RSS · CI watch RSS
- Public Health England portfolio CI
Frequently asked questions about Men C conjugate
What is Men C conjugate?
Who makes Men C conjugate?
What development phase is Men C conjugate in?
Related
- Manufacturer: Public Health England — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing